Table 7 Results from bio-assays using WHO cone test
Variable | 12 months | 24 months | 36 months |
|---|---|---|---|
Sud Ubangi (DuraNet©) | N = 30 | N = 30 | N = 30 |
Knockdown 60 min | |||
Mean (95% CI) | 95.6% (93.5–97.6) | 75.0% (67.3–82.7) | 97.8% (96.5–99.1) |
Median (IQR) | 96.0% (92.0– 100) | 74.0% (64.0–84.0) | 99.0% (96.3–100) |
Mortality 24 h | |||
Mean (95% CI) | 89.6% (82.9–96.3) | 92.2% (87.2–97.2) | 84.8% (77.7–2.0) |
Median (IQR) | 98.5% (79.0–100) | 94.0% (88.0–98.0) | 89.1% (77.7–5.4) |
Optimal effectiveness | |||
Estimate (95% CI) | 83.3% (63.4–93.5) | 86.7% (52.1–97.5) | 100% (-.-) |
Minimal effectiveness | |||
Estimate (95% CI) | 100% (-.-) | 100% (-.-) | 100% (-.-) |
Mongala (DawaPlus® 2.0) | N = 30 | N = 30 | N = 30 |
|---|---|---|---|
Knockdown 60 min | |||
Mean (95% CI) | 95.5% (92.7–98.2) | 86.6% (81.1–92.0) | 69.9% (61.0–8.8) |
Median (IQR) | 100% (92.0–100) | 90.0% (78.0–94.0) | 67.9% (60.5–9.5) |
Mortality 24 h | |||
Mean (95% CI) | 100% (-.-) | 92.6% (88.8–96.4) | 28.5% (21.1–5.8) |
Median (IQR) | 100% (-.-) | 96.0% (88.0–100) | 25.9% (10.7–1.7) |
Optimal effectiveness | |||
Estimate (95% CI) | 100% (-. -) | 90.0% (72.3–96.9) | 10.0% (2.9–28.9) |
Minimal effectiveness | |||
Estimate (95% CI) | 100% (-. -) | 100% (-.-) | 46.7% (30.9–3.1) |